7:45 Registration/Continental Breakfast
8:30 Chairperson's Opening Remarks
Adrian Bot, MD, Ph.D.
Chief Scientific Officer
Kite Pharma, Inc.
8:40 Active Immunization Against Cancer: From Bench to Bed
Dr. Brichard will cover the following in this presentation:
- Key science factors in immunotherapy programs
- clinical design
- Regulatory strategy
- Commercial challenges
Vincent G. Brichard, MD
Vice President & Head of Immunotherapeutics
GSK Biologicals
9:10 Cancer Vaccine Immunity in Melanoma and Hepatocellular Cancer
Cancer vaccines can promote increased antitumor immunity. When performed in a well-controlled and standardized fashion, immunologic responses can correlate with clinical outcomes. Recent studies suggest that in vivo cross priming can promote improved survival. In this presentation, Dr. Butterfield will discuss these study results and challenges that lie ahead.
Lisa Butterfield, Ph.D.
Associate Professor
Departments of Medicine, Surgery and Immunology
Director
UPCI Immunologic Monitoring & Cellular Products Laboratory
University of Pittsburgh School of Medicine
9:40 Presentation TBA
Mark Ahn, Ph.D.
President & Chief Executive Officer
Galena Biopharma
10:10 Refreshment Break/Poster Viewing
10:35 Recombinant Vector Cancer Vaccines as Monotherapy and in Combination Therapies
This presentation will cover the following:
- The importance of T-cell costimulation in vaccine efficacy
- The importance of appropriate clinical trial design and endpoints for vaccine therapy
- Points to consider in the use of vaccines in combination with other therapeutic modalities
- The development of a vaccine targeting the process of epithelial-to-mesenchymal transition (EMT)/”stemness”/drug resistance
Jeffrey Schlom, Ph.D.
Head, Immunotherapeutics Group Laboratory Chief
Laboratory of Tumor Immunology & Biology
National Cancer Institute, National Institutes of Health
11:05 The Cancer Immunotherapy Trials Network: Using the High-Priority Agents in Novel Therapeutic Strategies
Kim Margolin, MD
Professor
University of Washington School of Medicine
11:35 Autologous Proliferating Melanoma Cell Cultures: Fighting Fire with Fire in Cancer Immunotherapy
This presentation will cover the following:
- Antigen sources for immunotherapy: So many choices, why autologous?
- The process of purification and the challenges of scale up for autologous cell culture
- Cancer stem cells, cell culture and immunotherapy: bulk tumor vs. proliferating cell cultures
- Clinical results: the necessity of dendritic cells in vaccine preparations
Andrew Cornforth, Ph.D.
Cancer Stem Cell Program Manager
California Stem Cell
12:05 Lunch
1:15 New Strategies for Treatment and Prevention of Cervical & Prostate Cancers
W. Martin Kast, Ph.D.
Professor of Molecular Microbiology & Immunology, and Obstetrics & Gynecology
University of Southern California
1:45 A Phase II Trial for Dendritic Cell Immunotherapy in Patients with Glioblastoma
Marnix Bosch, Ph.D.
Chief Technical Officer
Northwest Biotherapeutics, Inc.
2:15 Interim Phase II Data for a Live Attenuated Listeria Immunotherapy for the Treatment of Progressive Metastatic Cervical Cancer
This presentation will cover the following:
- Preliminary safety and tolerance of Lm-LLO vaccines in late stage cancer patients.
- Preliminary efficacy of ADXS-HPV in patients who have failed surgery, radio &/or chemotherapy
- Future directions for Lm-LLO research
John Rothman, Ph.D.
Executive VP of Science & Operations
Advaxis, Inc.
2:45 Refreshment Break/Poster Viewing
3:15 Targeting Mesothelin-Expressing Tumors with Live-Attenuated Listeria monocytogenes
This presentation will cover the following:
- Attenuated and killed strains of Listeria monocytogenes
- Preclinical and clinical experience with Listeria-based therapeutic cancer vaccines
- Synergy between Listeria-based vaccines and other immunotherapies
- Combining two unapproved vaccine modalities targeting mesothelin for the treatment of patients with pancreatic cancer
Dirk Brockstedt, Ph.D.
VP Research & Development
Aduro Biotech
3:45 OMS ElectroOncology: DNA-Based Immunotherapy & Precision Tumor Destruction
Punit Dhillon
President & CEO
OncoSec Medical Inc.
4:15 (Tentative Title) An Investor's Perspective on Cancer Immunotherapy Research & Development
Mara Goldstein
Senior Healthcare Analyst
Cantor Fitzgerald
4:45 Cocktail Reception